Skip to main content
Annie De Groot, MD, Internal Medicine, Providence, RI

AnnieDe GrootMD

Internal Medicine Providence, RI

Allergy & Immunology, Infectious Disease

Founder and CEO/CSO EpiVax, Inc. from 1998 to 2024. As of 2024, Relinquished CEO-ship, now "Chairman and CSO" of EpiVax. Former Professor, Center for Vaccines and Immunology at University of Georgia, Founder, Interim Executive Director and Scientific Director GAIA Vaccine Foundation (Former), and Volunteer Executive Director and Medical Director, Clinica Esperanza/Hope Clinic (Former).

Dr. De Groot is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. De Groot's full profile

Already have an account?

  • Office

    188 Valley Street
    Suite 424
    Providence, RI 02909
    Phone+1 401-272-2123
    Fax+1 401-272-7562

Summary

  • Dr. Annie De Groot is a board-certified Internal Medicine physician who has primarily focused on biotechnology over the past 26 years. As founder and CEO of the EpiVax biotech company, based in Providence, Rhode Island, she has contributed to the development of new computational tools and methodologies for designing, developing, and approval of products in the Autoimmunity, Allergy, Immunology and Infectious Disease fields. She completed her education and early training at the University of Chicago and Tufts New England Medical Center. She was fellow in the Geographic Medicine (Infectious Diseases) program at NEMC, and she also completed a fellowship in vaccinology under Jay Berzofsky at the NIH (NIAID and NCI). Currently, she maintains a C-suite position at EpiVax, the company she established in Providence, Rhode Island in 1998. Her previous academic positions have included Senior Research Scientist at the University of Georgia and Director of the Institute for Immunology and Informatics at the University of Rhode Island. She was also faculty at the Brown University School of Medicine (now Warren Alpert Medical School). She is founder and board member of Clinica Esperanza/Hope Clinic, and GAIA Vaccine Foundation. Over the years, she has obtained research experience in immunology, vaccines, computational vaccinology, and providing free healthcare for the uninsured. She is widely published and has won awards including the AAPS Pharmaceutical Global Health Award and the Distinguished Alumni Award from University of Chicago Pritzker School of Medicine.
  • Executive Suite 10/11/2015: EpiVax CEO Annie De Groot

    Executive Suite: Dr. Annie De Groot, founder and CEO of the Providence-based biotech company EpiVax

Education & Training

  • Tufts Medical Center
    Tufts Medical CenterFellowship, Infectious Disease, 1989 - 1992
  • National Institutes of Health Clinical Center
    National Institutes of Health Clinical CenterFellowship, Allergy and Immunology, 1986 - 1989
  • Tufts Medical Center
    Tufts Medical CenterResidency, Internal Medicine, 1983 - 1986
  • University of Chicago Division of the Biological Sciences The Pritzker School of Medicine
    University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1983
  • Smith College
    Smith CollegeB.A., 1974 - 1978

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 1991 - 2026
  • RI State Medical License
    RI State Medical License 1992 - 2026
  • CT State Medical License
    CT State Medical License 1996 - 2006
  • DC State Medical License
    DC State Medical License 1986 - 1990
  • American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

  • 2020 AAPS Pharmaceutical Global Health Award American Association of Pharmaceutical Scientists, 2020
  • Distinguished Alumni Award University of Chicago Pritzker School of Medicine, 2019
  • CEO of the Year (2016) World Vaccine Congress, 2016
  • Join now to see all

Publications & Presentations

PubMed

Journal Articles

  • In Silico Vaccine Design: Accelerating the Response to BioThreats and Emerging Infectious Disease  
    Lenny Moise, Sarah Beseme, and Anne S. De Groot, IQT Quarterly, 1/1/2016
  • C3d adjuvant effects are mediated through the activation of C3d-specific autoreactive T cells  
    De Groot AS, Ross TM, Levitz L, Messitt TJ, Tassone R, Boyle CM, Vincelli AJ, Moise L, Martin W, Knopf PM, Immunol Cell Biol, 1/1/2015
  • Aspartate-beta-hydroxylase induces epitope-specific T cell responses in hepatocellular carcinoma  
    Tomimaru Y, Mishra S, Safran H, Charpentier KP, Martin W, De Groot AS, Gregory SH, Wands JR, Vaccine, 1/1/2015
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Abstracts/Posters

  • Development of Community-led Education Interventions for Human Papillomavirus Vaccination as a Model for Future HIV Vaccination Campaigns
    Karamoko Tounkara, Ibrahima Teguete, Eliza Squibb, Ben Aboubacar, Kotou Sangare, Sarah Beseme, Ousmane Koita, International Symposium for HIV and Emerging Infectious Diseases, Marseille, France, 1/25/2016
  • Development of community-led education about Human papillomavirus vaccination as a model for future HIV vaccination campaigns
    Karamoko Tounkara, Ibrahima Teguete, Eliza Squibb, Ben Aboubacar, Kotou Sangare, Sarah Beseme, Ousmane Koita, 15th European AIDS Conference, Barcelona, Spain, 1/21/2015
  • Assessment of HPV and cervical cancer knowledge, attitudes, practices and willingness to participate in an HPV vaccination program in Bamako, Mali
    Karamoko Tounkara, Ibrahima Teguete, Eliza Squibb, Ben Aboubacar, Youssouf Kone, Kotou Sangare, Sarah Beseme, Jennifer S. Smith, Ousmane Koita, A. S. De Groot, 30th International Papillomavirus Conference and Clinical and Public Health Workshops, Lisbon, Potrugal, 1/17/2015
  • Join now to see all

Lectures

  • Personalized Medicine for Biologics: Does HLA play a role in Immunogenicity? 
    Instituto Gulbenkian de Ciencia, Oeiras, Lisbon, Portugal - 1/23/2015
  • The Two-faced T cell epitope and the role of "Sel" and "Other" in Vaccine Efficacy 
    Netherlands National Institute for Public Health and the Environment (RIVM) and IntraVacc, Utrecht, - 1/18/2015
  • Tregitope Mediated Tolerance: The Role of HLA 
    Rotterdam, Netherlands - 1/17/2015
  • Join now to see all

Other

Other Languages

  • Spanish, French